P
Paul G. Richardson
Researcher at Harvard University
Publications - 1631
Citations - 174221
Paul G. Richardson is an academic researcher from Harvard University. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 183, co-authored 1533 publications receiving 155912 citations. Previous affiliations of Paul G. Richardson include Broomfield Hospital & Dartmouth College.
Papers
More filters
Journal ArticleDOI
First-in-human phase I study of the novel CELMoD agent CC-92480 combined with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
Paul G. Richardson,Annette Juul Vangsted,Karthik Ramasamy,Suzanne Trudel,Joaquín Martínez,Maria-Victoria Mateos,Paula Rodríguez Otero,Sagar Lonial,Rakesh Popat,Albert Oriol,Chatchada Karanes,Robert Z. Orlowski,Jesus G. Berdeja,Lilly Wong,Chenyang Shi,Manisha Lamba,Evelyn Barnett,Daniel W. Pierce,Michael Pourdehnad,Nizar J. Bahlis +19 more
TL;DR: CC-92480 is a novel cereblon E3 ligase modulator (CELMoD) agent designed for rapid, maximal degradation of Ikaros and Aiolos that has enhanced antiproliferative and tumoric properties in vitro.
Journal ArticleDOI
Current therapeutic uses of lenalidomide in multiple myeloma
TL;DR: Lenalidomide represents a new class of antitumour agents that is useful in the treatment of multiple myeloma and myelodysplastic syndromes and has received fast track designation from the FDA.
Journal ArticleDOI
Novel Three– and Four–Drug Combinations of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide, for Newly Diagnosed Multiple Myeloma: Encouraging Results From the Multi-Center, Randomized, Phase 2 EVOLUTION Study.
Shaji Kumar,Ian W. Flinn,Parameswaran Hari,Natalie S. Callander,Stephen J. Noga,A. Keith Stewart,Jonathan Glass,Noopur Raje,Robert M. Rifkin,Hongliang Shi,Iain J. Webb,Paul G. Richardson,S. Vincent Rajkumar +12 more
TL;DR: Results from the phase 1 dose-escalation portion of the multi-center EVOLUTION study showed that the VDCR regimen is a highly active and generally well-tolerated induction therapy in previously untreated multiple myeloma patients (pts).
Journal ArticleDOI
Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma
Xavier Leleu,Tamás Masszi,Nizar J. Bahlis,Luisa Viterbo,Bartrum W Baker,Peter Gimsing,Vladimir Maisnar,Olga Samoilova,Laura Rosiñol,Christian Langer,Kevin W. Song,Tohru Izumi,Charles S. Cleeland,Deborah Berg,Huamao Mark Lin,Yanyan Zhu,Tomas Skacel,Tomas Skacel,Philippe Moreau,Paul G. Richardson +19 more
TL;DR: It is demonstrated that addition of ixazomib to Rd significantly improved efficacy while HRQoL was maintained, reflecting the limited additional toxicity seen with IRd versus placebo‐Rd, and support the feasibility of long‐term IRd administration.
Journal ArticleDOI
Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance
Shaji Kumar,Jesus G. Berdeja,Ruben Niesvizky,Sagar Lonial,Jacob P. Laubach,Mehdi Hamadani,A. Keith Stewart,Parameswaran Hari,Vivek Roy,Robert Vescio,Jonathan L. Kaufman,Deborah Berg,Eileen Liao,Eileen Liao,S. Vincent Rajkumar,Paul G. Richardson +15 more
TL;DR: Weekly IRd, followed by ixazomib maintenance, was highly active with acceptable toxicity, enabling long-term administration with no evidence of cumulative toxicities.